The lead time is within 15 workdays for both peak and off-peak seasons
Overview of clinical trials In the wake of phase I and phase II trials promising results, the clinical trials of phase III (Table 1) were designed to evaluate the safety and efficacy of tirzepatide for improving glycemic control in patients with T2DM in eight published SURPASS trials (SURPASS 1-5, SURPASS J-mono, and SURPASS J-combo) [8-10,25-28] and for treating obesity in the SURMOUNT trial (SURMOUNT-1) [29]
Tailoring protocols to specific study goals enhances research relevance and outcome quality
Q4 2026 (earliest) New Drug Application (NDA) filing with the FDA
Units measure volume, not dosage, which is why a reverse conversion is sometimes needed
Oakes: Writing review & editing, Writing original draft, Resources, Methodology, Investigation, Data curation, Conceptualization